A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

Phase 2

Recruiting

• Conditions: Graves Disease
• Interventions: Drug: IMVT-1401 (batoclimab)

• Registration Number: NCT05907668
• Lead Sponsor: Immunovant Sciences GmbH

Brief Summary

The purpose of this study is to assess the efficacy and safety of 24 weeks of treatment with batoclimab in adult participants with biochemically documented hyperthyroidism due to GD who have failed to achieve euthyroidism on antithyroid drugs (ATDs).

Detailed Description

Not available

Study Timeline

• Study Start: 2023-05-15
• Study First Submitted: 2023-05-15
• Study First Submitted QC: 2023-06-07
• Study First Posted: 2023-06-18
• Last Update Submitted: 2023-08-31
• Status Verified: 2023-09
• Last Update Posted: 2023-09-05
• Primary Completion: 2024-11
• Study Completion: 2025-05

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• Have serologically confirmed GD as documented by presence of elevated stimulatory thyrotropin receptor antibody (TSH-R-Ab) level (i.e., > specimen-to-reference ratio of 140%) at the Screening Visit.

• Have active hyperthyroidism due to GD with the following laboratory values at the Screening Visit:

  • TSH < LLN
  • FT3 > upper limit of normal (ULN) and <=5 * ULN
  • FT4 > ULN and <=5 * ULN

Note: Participants who have T3 thyrotoxicosis (i.e TSH <LLN, FT3 > ULN and ≤5× ULN, but FT4 within normal range) at the Screening Visit may be enrolled, if they have serologically confirmed GD as per Inclusion Criterion 1.

• Are willing and capable of giving written informed consent, which includes being able to comply with all aspects of the study treatment and testing schedule.

Read More

Exclusion Criteria

• History of hyperthyroidism not caused by GD (e.g., toxic adenoma or toxic multinodular goiter), and/or history or presence of thyroid storm.
• History of treatment with radioactive iodine or thyroid surgery.
• Total immunoglobulin G (IgG) level <6 grams per liter (g/L) at the Screening Visit.
• Albumin level <3.5 grams per deciliter (g/dL) (<35 g/L) at the Screening Visit.
• Absolute neutrophil count <1000 cells per cubic millimeter (cells/mm^3) at the Screening Visit.

Other, more specific exclusion criteria are defined in the protocol.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Batoclimab	IMVT-1401 (batoclimab)	Participants will receive batoclimab 680 milligrams (mg) subcutaneously (SC) weekly (QW) injection for 12 weeks followed by 340 mg SC QW for 12 weeks.

Primary Outcome Measures

Name	Time	Method
Percentage of participants who achieve normalization of free triiodothyronine (FT3) and free thyroxine (FT4), or have FT3 and/or FT4 below the lower limit of normal (LLN) at week 24 without increase in ATD dose	At Week 24

Secondary Outcome Measures

Name	Time	Method
Percentage of participants who achieve normalization of FT3 and FT4 at Week 24 with ATD dose <= 50% of the ATD dose at Week 24	At Week 24
Percentage of participants who are off ATD treatment and achieve normalization of FT3 and FT4, or have FT3 and/or FT4 below the LLN at Week 24	At Week 24

Trial Locations

Locations (1)

Site Number - 6505; 🇩🇪 Mainz, Germany